DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
ANX-510 is an investigational drug.
There have been 10 clinical trials for ANX-510. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2006.
The most common disease conditions in clinical trials are Rectal Neoplasms, Lymphoma, Non-Hodgkin, and Delirium. The leading clinical trial sponsors are Mast Therapeutics, Inc., Thywill Latam Solutions SRL, and University of Sao Paulo.
Recent Clinical Trials for ANX-510
|Epigenetics in PostOperative Pediatric Emergence Delirium||University of Sao Paulo||N/A|
|Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome||National Heart, Lung, and Blood Institute (NHLBI)||Phase 1|
|Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome||National Institutes of Health (NIH)||Phase 1|